Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00405119 | A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine. | PHASE2 | COMPLETED | 92 | — | — | May 1, 2006 | Mar 1, 2007 | Jan 19, 2017 | 2 | Australia |
| Name | Type | Description |
|---|---|---|
| AH23844 (lavoltidine) | DRUG | - |
| NEXIUM (esomeprazole) | DRUG | - |
| ZANTAC (ranitidine) | DRUG | - |
Inclusion criteria: * Subject must have a Body Mass Index (BMI) from 19-30 kg/m2 * Subject does not present with abnormal clinical lab findings * Subject is able to tolerate a nasogastric pH electrode. Exclusion criteria: * Subject is Helicobacter-positive on a C13 urea breath test * Subject has ...